OmniAb, Inc. SEC Filings

Schedule 13G/A filed for OmniAb, Inc. (OABI) discloses that several related entities and individuals report beneficial ownership of the issuer's common stock. Ash X LP and RLG GP each report ownership of 8,271,347 shares, representing approximately 5.8% of the outstanding common stock. RLG Capco II LLC holds 1,800,246 shares (about 1.3%) and Joel Greenblatt holds 1,428,571 shares (about 1.0%). Robert Goldstein is reported as beneficial owner of 10,071,593 shares (about 7.0%), reflecting combined holdings through entities he controls. The percentages are calculated using 122,701,294 shares outstanding as of July 30, 2025 plus 21,254,106 additional shares issued on August 25, 2025. The filing states the holdings are not intended to influence control of the issuer.

OmniAb, Inc. (OABI) insider purchase reported by President, CEO and Director Matthew W. Foehr. On 08/26/2025 Mr. Foehr acquired 540,540 shares of common stock in a private placement at $1.85 per share, the closing price on 08/22/2025. After this transaction he beneficially owns 4,341,987 shares in total, which includes 5,211 shares purchased under the company ESPP on 05/30/2025. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on Mr. Foehr's behalf.

OmniAb, Inc. reported the execution of a Securities Purchase Agreement dated August 24, 2025 between the company and the purchasers party thereto and issued a related press release dated August 25, 2025. The filing notes the transaction is subject to customary closing conditions and highlights risks and uncertainties tied to market conditions and satisfaction of those conditions. The company includes a standard forward-looking statements caution and disclaims any obligation to update such statements. The filing is signed by Charles S. Berkman, Chief Legal Officer and Secretary.

Whitefort Capital Management and two co-managing partners report beneficial ownership of 10,240,146 shares of OmniAb, Inc. (OABI), representing 8.4% of the outstanding common stock as of June 30, 2025. The filing states Whitefort Management acts as investment manager for client accounts holding these shares, and Co-Managing Partners David Salanic and Joseph Kaplan may be deemed to beneficially own the same block due to their roles. The 8.4% figure is based on 122,335,336 shares outstanding as of May 1, 2025. The statement affirms the position is not held to change or influence control of the issuer.

Janus Henderson Group plc reports a small, passive holding in OmniAb, Inc.'s common stock, amounting to roughly 945,956 shares which the filing states represents 0.8% of the class. The disclosure shows the firm has shared voting and dispositive power over these shares (no sole voting or dispositive power reported), and the filing identifies indirect subsidiaries (JHIUS, JHIUKL and JHIAIFML) as registered investment advisers providing advice to managed portfolios.

The filing includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The filing also includes a power of attorney authorizing designated compliance officers to execute ownership reports on the company's behalf.

OmniAb, Inc. (OABI) Q2 2025 condensed summary. Total revenue was $3.897 million for the three months ended June 30, 2025 versus $7.614 million in Q2 2024. Net loss was $15.875 million in Q2 2025 versus $13.631 million in Q2 2024; six-month net loss was $34.075 million versus $32.592 million prior-year. Cash and cash equivalents declined to $18.281 million and short-term investments were $23.334 million as of June 30, 2025.

Operational and liquidity highlights: the filing reports 100 active partners and 381 active programs, including 28 OmniAb-derived antibodies in clinical development, one under regulatory review, and three approved partner products. Management states existing cash, cash equivalents and short-term investments are sufficient to support operations for at least the next 12 months. The company recognized a $3.0 million gain from sale of an ion channel asset in Q2 2025.

OmniAb, Inc. (OABI) – Form 4 filed 18-Jun-2025

Director Steven Love reported several equity transactions dated 17-Jun-2025. The filing shows a routine mix of RSU vesting, fresh equity grants and the associated increase in directly held common shares.

• RSU vesting (Code M): 20,000 previously awarded restricted stock units converted into an equal number of common shares. Mr. Love’s direct shareholdings rose to 58,333 shares following the conversion.
• New RSU grant (Code A): 20,000 RSUs were awarded. These units vest in full on the earlier of OmniAb’s next annual shareholder meeting or the first anniversary of the grant date.
• New stock option grant (Code A): 40,000 options with a strike price of $1.70 and a 10-year term (expiring 17-Jun-2035) were issued. The option vests in full on the same schedule as the RSUs.

Post-transaction derivative holdings now comprise 46,667 RSUs and 40,000 stock options, while non-derivative ownership stands at 58,333 common shares. No open-market sales were disclosed, indicating that all changes stem from equity compensation and not from dispositions that might pressure the share float.

Because the reported activities involve standard director compensation and do not reflect purchases or sales on the open market, the filing is generally viewed as neutral-to-slightly-positive: it aligns the director’s incentives with shareholders without signaling divestiture. Material financial performance data is not included in this filing.